[{"id":"b7618037-1369-4803-9a4d-36cc465a98d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159906","created_at":"2025-09-13T08:44:39.729Z","updated_at":"2025-09-13T08:44:39.729Z","phase":"Phase 1/2","brief_title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT07159906","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/08/2025","start_date":" 09/08/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-09-08"},{"id":"c72ecd8f-9c23-45c8-aceb-c2281207ef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT07141771","created_at":"2025-08-30T13:51:58.696Z","updated_at":"2025-08-30T13:51:58.696Z","phase":"Phase 1/2","brief_title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","source_id_and_acronym":"NCT07141771","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • etoposide IV • irinotecan • topotecan • AiRuiYi (fluzoparib) • Zepzelca (lurbinectedin) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-08-26"},{"id":"9de3eb66-06bd-4d1a-92a9-adae61b8b59a","acronym":"Acclaim-1","url":"https://clinicaltrials.gov/study/NCT04486833","created_at":"2021-01-18T21:32:20.912Z","updated_at":"2025-02-25T12:27:38.683Z","phase":"Phase 1/2","brief_title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","source_id_and_acronym":"NCT04486833 - Acclaim-1","lead_sponsor":"Genprex, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • Reqorsa (quaratusugene ozeplasmid)"],"overall_status":"Recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 09/03/2021","start_date":" 09/03/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-02-24"},{"id":"9a0a8faa-2764-48be-bddc-53cde9f97223","acronym":"LiFFT","url":"https://clinicaltrials.gov/study/NCT05918640","created_at":"2023-06-26T14:09:13.345Z","updated_at":"2025-02-25T15:13:34.219Z","phase":"Phase 1/2","brief_title":"Lurbinectedin in FET-Fused Tumors","source_id_and_acronym":"NCT05918640 - LiFFT","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4","pipe":"","alterations":" ","tags":["EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-13"},{"id":"fcb868e2-5523-48f4-b199-227a152f0dc1","acronym":"LURBIMUNE","url":"https://clinicaltrials.gov/study/NCT05572476","created_at":"2022-10-07T14:00:03.928Z","updated_at":"2025-02-25T15:00:40.239Z","phase":"Phase 2","brief_title":"Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer","source_id_and_acronym":"NCT05572476 - LURBIMUNE","lead_sponsor":"Institut Bergonié","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • etoposide IV • Zepzelca (lurbinectedin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2024-06-05"},{"id":"893adf5f-401b-45ed-b55a-95592085576f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04874194","created_at":"2021-05-05T11:52:46.095Z","updated_at":"2024-07-02T16:35:02.356Z","phase":"Phase 1/2","brief_title":"Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1","source_id_and_acronym":"NCT04874194","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RUNX1","pipe":" | ","alterations":" RUNX1 mutation","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-21"},{"id":"e2cd7df4-a3bf-46be-9b4c-885f319f5bef","acronym":"PM1183-A-014-15","url":"https://clinicaltrials.gov/study/NCT02611024","created_at":"2021-12-03T00:53:57.424Z","updated_at":"2024-07-02T16:35:06.918Z","phase":"Phase 1/2","brief_title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","source_id_and_acronym":"NCT02611024 - PM1183-A-014-15","lead_sponsor":"PharmaMar","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 05/06/2016","start_date":" 05/06/2016","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-30"},{"id":"b73496d5-e698-47e5-b7a2-1ea85e0d187e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696784","created_at":"2021-01-18T18:07:07.182Z","updated_at":"2024-07-02T16:35:07.400Z","phase":"Phase 1","brief_title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","source_id_and_acronym":"NCT03696784","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2043","study_completion_date":" 03/22/2043","last_update_posted":"2024-04-26"},{"id":"494a3a47-09dc-456f-a62d-fc7e845bfb64","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016377","created_at":"2021-01-18T14:50:40.602Z","updated_at":"2024-07-02T16:35:08.102Z","phase":"Phase 1/2","brief_title":"Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL","source_id_and_acronym":"NCT03016377","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ABL1 • BCR • CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["ABL1 • BCR • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • iC9-CAR19 cells • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/22/2012","start_date":" 03/22/2012","primary_txt":" Primary completion: 04/22/2026","primary_completion_date":" 04/22/2026","study_txt":" Completion: 04/22/2041","study_completion_date":" 04/22/2041","last_update_posted":"2024-04-23"},{"id":"ac98ef23-c100-4250-a77b-e2d769f12f8d","acronym":"NCI-2020-02940","url":"https://clinicaltrials.gov/study/NCT04445844","created_at":"2021-01-18T21:23:42.652Z","updated_at":"2024-07-02T16:35:11.834Z","phase":"Phase 2","brief_title":"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","source_id_and_acronym":"NCT04445844 - NCI-2020-02940","lead_sponsor":"Mridula George, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Zynyz (retifanlimab-dlwr) • Reolysin (pelareorep)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-04-02"},{"id":"519407a2-e161-4bce-9dc1-be6550116e9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800587","created_at":"2023-04-05T14:03:42.889Z","updated_at":"2024-07-02T16:35:12.781Z","phase":"Phase 2","brief_title":"Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer","source_id_and_acronym":"NCT05800587","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • docetaxel • albumin-bound paclitaxel • pemetrexed • etoposide IV • irinotecan • topotecan • Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 02/22/2023","start_date":" 02/22/2023","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2024-03-26"},{"id":"a40edb33-4956-4fcb-af35-db7081c0b606","acronym":"","url":"https://clinicaltrials.gov/study/NCT06328179","created_at":"2024-03-25T17:36:14.935Z","updated_at":"2024-07-02T16:35:12.972Z","phase":"","brief_title":"Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.","source_id_and_acronym":"NCT06328179","lead_sponsor":"Huai'an First People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-03-25"},{"id":"3cd29e52-af9d-4ffc-9f57-b8ce426e67cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05661201","created_at":"2022-12-22T15:59:18.931Z","updated_at":"2024-07-02T16:35:15.432Z","phase":"Phase 1","brief_title":"NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors","source_id_and_acronym":"NCT05661201","lead_sponsor":"Georgetown University","biomarkers":" KRAS • ST2","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Nerofe (84AA-API 14AA)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/12/2023","start_date":" 04/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-03-11"},{"id":"07d712f7-22e2-4f57-ad7d-c2400a080233","acronym":"EMERGE-201","url":"https://clinicaltrials.gov/study/NCT05126433","created_at":"2021-11-19T13:53:37.793Z","updated_at":"2024-07-02T16:35:17.551Z","phase":"Phase 2","brief_title":"Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201)","source_id_and_acronym":"NCT05126433 - EMERGE-201","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2 • HRD","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 03/03/2022","start_date":" 03/03/2022","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-02-26"},{"id":"868293a8-a265-41a4-8e63-93c5f8993ec3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02704858","created_at":"2021-02-25T12:16:38.279Z","updated_at":"2024-07-02T16:35:19.174Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","source_id_and_acronym":"NCT02704858","lead_sponsor":"Neonc Technologies, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e perillyl alcohol (NEO100)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 04/08/2016","start_date":" 04/08/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-15"},{"id":"731ab927-ac32-42ee-9011-baa1124b987d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05229588","created_at":"2022-02-12T17:48:13.004Z","updated_at":"2024-07-02T16:35:21.201Z","phase":"Phase 2","brief_title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","source_id_and_acronym":"NCT05229588","lead_sponsor":"HonorHealth Research Institute","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-02-02"},{"id":"cf834b01-5b9b-4c32-bb23-b221bf405680","acronym":"","url":"https://clinicaltrials.gov/study/NCT02653976","created_at":"2021-01-18T12:55:59.721Z","updated_at":"2024-07-02T16:35:22.114Z","phase":"Phase 2","brief_title":"A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT02653976","lead_sponsor":"Solasia Pharma K.K.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zinapar (darinaparsin)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 03/25/2016","start_date":" 03/25/2016","primary_txt":" Primary completion: 10/11/2020","primary_completion_date":" 10/11/2020","study_txt":" Completion: 06/17/2021","study_completion_date":" 06/17/2021","last_update_posted":"2024-01-26"},{"id":"6cdd3cff-a8f2-4076-b8fb-2e4bb4de86c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04120246","created_at":"2021-01-18T20:08:08.496Z","updated_at":"2024-07-02T16:35:26.492Z","phase":"Phase 1","brief_title":"Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer","source_id_and_acronym":"NCT04120246","lead_sponsor":"Veana Therapeutics","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • GB221 (coprelotamab) • Vimo (alpha-tocopheroloxyacetic acid)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-12-12"},{"id":"dc767eda-b996-43e4-bac4-42c5a7f4d226","acronym":"BRACELET-1","url":"https://clinicaltrials.gov/study/NCT04215146","created_at":"2021-01-18T20:31:29.086Z","updated_at":"2024-07-02T16:35:27.596Z","phase":"Phase 2","brief_title":"A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study","source_id_and_acronym":"NCT04215146 - BRACELET-1","lead_sponsor":"Oncolytics Biotech","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Bavencio (avelumab) • Reolysin (pelareorep)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 06/10/2020","start_date":" 06/10/2020","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-11-30"},{"id":"b3af7af9-f90a-43d8-a825-1d8fe6b331f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05519059","created_at":"2022-08-29T13:03:02.753Z","updated_at":"2024-07-02T16:35:28.248Z","phase":"Phase 1","brief_title":"Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05519059","lead_sponsor":"Adlai Nortye Biopharma Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Reolysin (pelareorep)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/11/2021","start_date":" 10/11/2021","primary_txt":" Primary completion: 09/29/2022","primary_completion_date":" 09/29/2022","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2023-11-22"},{"id":"4c303da3-0333-482c-a447-3a810066c7aa","acronym":"AMBUSH","url":"https://clinicaltrials.gov/study/NCT05514990","created_at":"2023-11-18T23:15:37.982Z","updated_at":"2024-07-02T16:35:28.859Z","phase":"Phase 1/2","brief_title":"Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial","source_id_and_acronym":"NCT05514990 - AMBUSH","lead_sponsor":"University of Southern California","biomarkers":" CD8 • PD-1 • IFNG • CD4 • GZMB","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bortezomib • Reolysin (pelareorep) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2026","study_completion_date":" 10/07/2026","last_update_posted":"2023-11-17"},{"id":"6652628c-ad51-4797-8f15-72f4094ba21f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05578326","created_at":"2022-10-13T17:58:14.557Z","updated_at":"2024-07-02T16:35:29.032Z","phase":"Phase 2","brief_title":"Study of Trilaciclib and Lurbinectidin","source_id_and_acronym":"NCT05578326","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin) • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 07/25/2024","primary_completion_date":" 07/25/2024","study_txt":" Completion: 07/25/2026","study_completion_date":" 07/25/2026","last_update_posted":"2023-11-16"},{"id":"d3fbe9fc-cb0c-4ea4-a0c8-0aaa88366b82","acronym":"TUD-APOLLO-064","url":"https://clinicaltrials.gov/study/NCT02688140","created_at":"2022-03-24T01:54:02.216Z","updated_at":"2024-07-02T16:35:30.678Z","phase":"Phase 3","brief_title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02688140 - TUD-APOLLO-064","lead_sponsor":"Technische Universität Dresden","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-11-02"},{"id":"4dacc8db-356a-480d-b423-f6e0b948d9b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04607954","created_at":"2021-01-19T20:31:50.970Z","updated_at":"2024-07-02T16:35:42.142Z","phase":"Phase 2","brief_title":"Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer","source_id_and_acronym":"NCT04607954","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • topotecan • Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-07-24"}]